Several reports have documented rapid changes in treatment patterns of anemia for hemodialysis patients with end-stage renal disease (ESRD) shortly after these events: lower ESA doses, lower Hb levels, greater intravenous iron use [5–9], and increased rates of patients receiving red blood cell transfusions [5, 7]. The gene discussed is GSTM1; the disease is chronic kidney disease.